Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Dr. Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Commonwealth Scientific and Industrial Research Organisation | Australia

Dr. Michela Simone is a distinguished scientist with expertise spanning green chemistry, renewable energy, carbohydrate chemistry, glycobiology, ionic liquids, spectroscopy, medicinal chemistry, and synthetic developments. With a multicultural background and fluency in multiple languages, she has built a global research profile, contributing significantly to sustainability and pharmaceutical sciences. Currently serving as a Research Scientist at CSIRO in Australia, she leads and supports projects focused on sustainable carbon technologies and carbon capture efficiency. Her earlier career included leadership as a CERC Fellow at CSIRO, lecturer roles at the University of Newcastle and University of Sydney, and postdoctoral research at the University of Oxford and University College London. She has published extensively in high-impact journals, authored book chapters, and holds patents in hydrogen production and drug development. Her academic and industrial collaborations highlight her interdisciplinary approach, bridging fundamental research with applied solutions to address pressing global challenges in energy, health, and sustainability.

Profile

Google scholar

ORCID

Education

Dr. Michela Simone earned her Doctor of Philosophy from the University of Oxford, where she conducted pioneering research on branched sugar lactones under the mentorship of Professor George W. J. Fleet at the Dyson Perrins Laboratory and Chemistry Research Laboratory. Prior to this, she completed her Master of Science with first-class honours at the Victoria University of Manchester, focusing on the synthesis of muscarinic receptor agonists under Professor E. James Thomas. During her studies, she was awarded a European Union Socrates Award for an exchange program at the Georg-August University of Göttingen in Germany, where she worked on chemical and biological syntheses of pyripyropenes under Professor Uwe Beifuss. This international academic training provided her with a strong foundation in synthetic organic chemistry, carbohydrate chemistry, and medicinal chemistry. Her educational journey laid the groundwork for her later achievements in spectroscopy, drug discovery, and renewable energy research, demonstrating her ability to bridge chemistry with interdisciplinary applications.

Experience

Dr. Michela Simone’s professional journey reflects a balance of academic scholarship, research innovation, and industrial collaboration. Currently, she works at CSIRO as a Research Scientist in the Sustainable Carbon Technologies Group, where she applies her mechanistic and spectroscopic expertise to optimize carbon capture processes for industrial applications. Previously, as a CERC Fellow at CSIRO, she led a major project on sustainable hydrogen production, integrating physical chemistry, engineering, and physics, resulting in a patent for water-splitting processes. Her academic career includes tenure as a Lecturer in Medicinal Chemistry and Chemical Biology at the University of Newcastle, where she managed a 40:40:20 workload across research, teaching, and service while supervising her research group in glycobiology and synthetic chemistry. Earlier, she was a Lecturer in Chemistry at the University of Sydney, focusing on medicinal and biological chemistry. Her postdoctoral work at Oxford and University College London contributed to advances in protein interactions and medicinal chemistry.

Awards and Honors

Dr. Michela Simone’s career has been marked by recognition for her contributions to chemistry and interdisciplinary research. She has authored more than sixty-five peer-reviewed publications, invited book chapters, and holds patents in hydrogen production technologies and drug delivery systems, reflecting her innovative impact on both energy and healthcare. Her invited contributions to special issues in journals such as Molecules, Pharmaceuticals, and the European Journal of Medicinal Chemistry highlight her status as a recognized expert in boron chemistry, glycobiology, and green synthetic methods. She has been invited to contribute book chapters with leading publishers including Taylor & Francis, underscoring her international reputation. Her work has been spotlighted in editorial features such as “Women in Bioorganic Chemistry,” reflecting her role as a leader and role model in science. With a growing citation record, high h-index, and strong collaborations across academia and industry, she continues to be acknowledged for her research excellence and scientific leadership.

Research Focus

Dr. Michela Simone’s research focus lies at the intersection of green chemistry, renewable energy, and medicinal chemistry, with an emphasis on practical applications that address urgent global challenges. She has pioneered work in renewable fuels, including hydrogen generation, biomass conversion, carbon capture and storage, and redox flow batteries, aiming to reduce environmental impact while improving energy efficiency. Her work in carbohydrate chemistry and glycobiology has contributed to the development of high and low Fsp3 drug leads, with innovative approaches incorporating organic boron as a novel pharmacophore for medicinal chemistry and cancer therapies. She has also advanced the field of ionic liquids, exploring their potential in sustainable synthesis and material applications. Utilizing spectroscopy and mechanistic insights, she combines fundamental chemical principles with applied solutions, leading to patents and industrial collaborations. Her interdisciplinary approach integrates chemistry, physics, and engineering, establishing her as a global leader in research that bridges sustainability, energy innovation, and health.

 

Publications

 

Title: Endothelial C-type natriuretic peptide maintains vascular homeostasis
Year: 2014
Citation: 187

Title: The expanding utility of continuous flow hydrogenation
Year: 2015
Citation: 144

Title: Synchrotron based NEXAFS study on nitrogen doped hydrothermal carbon: Insights into surface functionalities and formation mechanisms
Year: 2017
Citation: 126

Title: A compendium of sugar amino acids (SAA): scaffolds, peptide-and glyco-mimetics
Year: 2007
Citation: 121

Title: Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis
Year: 2016
Citation: 111

Title: A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues
Year: 2013
Citation: 103

Title: Kiliani on ketoses: branched carbohydrate building blocks from D-fructose and L-sorbose
Year: 2004
Citation: 87

Title: Kiliani reactions on ketoses: branched carbohydrate building blocks from D-tagatose and D-psicose
Year: 2005
Citation: 79

Title: o-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity
Year: 2019
Citation: 52

Conclusion

Dr. Michela Simone is an accomplished scientist whose interdisciplinary expertise in green chemistry, renewable energy, carbohydrate chemistry, and medicinal chemistry has led to impactful research, patents, and collaborations that advance sustainability and healthcare innovation worldwide.

Milana Frenkel-Morgenstern | Liquid Biopsy | Women Researcher Award

Dr. Milana Frenkel-Morgenstern | Liquid Biopsy | Women Researcher Award

Dr. Milana Frenkel-Morgenstern is an Israeli scientist and Principal Investigator at the Scojen Institute of Synthetic Biology, Reichman University. She specializes in bioinformatics, systems biology, and synthetic biology. With a rich background spanning molecular genetics, computer science, and structural biology, she has held key positions in institutions such as Bar-Ilan University, Weizmann Institute of Science, and the Spanish National Research Centre. She is renowned for her pioneering work in liquid biopsies, chimeric RNAs, and non-invasive diagnostic tools. Dr. Frenkel-Morgenstern has published extensively, served on prestigious evaluation panels, and received numerous fellowships and awards, including the Miguel Servet Fellowship and the Rector Prize for Scientific Innovation. Her leadership in both academic and public scientific communities, combined with a strong record of mentorship and university service, highlights her influential presence in biomedical research. She is also the founder of the “Art in Science” session at ISMB, reflecting her commitment to interdisciplinary innovation.

Profile

🎓 Education

Dr. Frenkel-Morgenstern earned her PhD in Molecular Genetics at the Weizmann Institute of Science under Prof. Shmuel Pietrokovski, specializing in bioinformatics and systems biology. Prior to that, she completed her MSc in Mathematics and Computer Science with a thesis in molecular biology from Bar-Ilan University, mentored by Prof. Ron Unger and Prof. Amihood Amir. Her undergraduate studies were also at Bar-Ilan University, where she earned a BSc in Mathematics and Computer Science. Her multidisciplinary education seamlessly blends life sciences, computational modeling, and mathematical analysis, forming the foundation for her later innovations in biomedical research. This strong computational background, coupled with a deep understanding of molecular biology, positioned her to excel in complex systems analysis, machine learning, and genomics, leading to a distinguished academic and research career. Her training has enabled her to lead translational biomedical projects, particularly in the fields of cancer research, structural bioinformatics, and synthetic biology.

🧪 Experience

Dr. Milana Frenkel-Morgenstern has over two decades of academic and research experience. She is currently Principal Investigator and Senior Lecturer at Reichman University. Prior to this, she was a senior faculty member at Bar-Ilan University’s Azrieli Faculty of Medicine for a decade. Internationally, she served as a staff scientist at the Spanish National Cancer Research Centre (CNIO) and was a postdoctoral fellow in the labs of Prof. Alfonso Valencia and Prof. Uri Alon. She has also been a scientific advisor and educator at the Weizmann Institute’s Davidson Institute. Dr. Frenkel-Morgenstern has taught a range of graduate-level courses in genomics, bioinformatics, and computational biology. She has been deeply involved in institutional governance, serving on data science boards, senate committees, and multiple departmental leadership roles. Her professional journey reflects a blend of research excellence, teaching dedication, and scientific outreach, including organizing the “Art in Science” initiative for ISMB/ECCB.

🏅 Awards and Honors

Dr. Frenkel-Morgenstern has received numerous prestigious awards recognizing her research and innovation. She was awarded the Rector Prize for Scientific Innovation by Bar-Ilan University in 2021, and the Bioinfo4Women Fellowship by the Barcelona Supercomputing Center from 2016–2019. Her work on RNA sequencing earned her the Miguel Servet Fellowship (2011–2015), and she received international postdoctoral fellowships from Caja Navarra Foundation and Horvitz Foundation. Her academic contributions have been recognized through several Travel Awards from ISMB, ECCB, and RECOMB, and she earned Outstanding Poster Awards in international conferences. As a guest editor for leading journals and evaluator for major funding bodies (ERC, ISF, GIF, etc.), her influence extends beyond research to shaping the global scientific agenda. She also received the Excellent Lecturer Award (2017) at Bar-Ilan University and serves as an academic reviewer and thesis evaluator for institutions across Israel, Europe, and Asia, demonstrating global academic leadership.

🔬 Research Focus

Dr. Frenkel-Morgenstern’s research centers on liquid biopsy technologies, cell-free nucleic acids (cfDNA/cfRNA), and systems and synthetic biology. Her lab investigates molecular biomarkers for cancer, arthritis, and prenatal diagnostics, developing computational platforms that utilize next-generation sequencing, AI, and machine learning. She explores chimeric RNAs, chromosomal translocations, and non-optimal codon usage, linking genetic regulation with disease mechanisms. Her interdisciplinary work bridges microbiome analysis, metagenomics, genome profiling, and protein-protein interaction networks, with translational applications in personalized medicine. In addition, she applies big data analytics to understand the cell cycle, identify druggable targets, and improve early diagnostics using non-invasive methods. Dr. Frenkel-Morgenstern is also investigating novel areas such as the relationship between melanin, Vitamin D, and mRNA technologies, relevant to both clinical and cosmetic science. Her research is both hypothesis-driven and data-intensive, aiming to convert large-scale biological data into practical medical insights and biotechnology solutions with significant societal impact.

Conclusion

Dr. Milana Frenkel-Morgenstern is a leading scientist in bioinformatics and synthetic biology whose interdisciplinary research in liquid biopsies, systems biology, and AI-driven genomics continues to impact cancer diagnostics and translational medicine globally.

Publications
  • Applications for Circulating Cell-Free DNA in Oral Squamous Cell Carcinoma: A Non-Invasive Approach for Detecting Structural Variants, Fusions, and Oncoviruses

    Cancers
    2025-06 | Journal article | Author
    CONTRIBUTORS: Mahua Bhattacharya; Dan Yaniv; Dylan P. D’Souza; Eyal Yosefof; sharon tzelnick; Rajesh Detroja; Tal Wax; Adva Levy-Barda; Gideon Baum; Aviram Mizrachi et al.
  • ChiTaRS 8.0: the comprehensive database of chimeric transcripts and RNA-seq data with applications in liquid biopsy

    Nucleic Acids Research
    2025-01-06 | Journal article
    CONTRIBUTORS: Dylan DSouza; Lihi Bik; Olawumi Giwa; Shahaf Cohen; Hilit Levy Barazany; Tali Siegal; Milana Frenkel-Morgenstern
  • The applications of circulating cell-free DNA for oral squamous cell carcinoma patients as non-invasive diagnostics of structural variants, fusions and oncoviruses

    2023-11-30 | Preprint
    CONTRIBUTORS: Mahua Bhattacharya; Dan Yaniv; Eyal Yosefof; Sharon Tzelnick; Rajesh Detroja; Dylan P. D’Souza; Gidi Baum; Aviram Mizrachi; Gideon Bachar; Milana Frenkel Morgenster

Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi 🇺🇸 is a passionate radiation oncologist with a dynamic academic and clinical background, currently serving as Chief Resident at Allegheny Health Network in Pittsburgh, PA 💼. She combines a global medical foundation from Iran with extensive U.S. clinical training 🇮🇷➡️🇺🇸. Driven by innovation and compassion, Parisa has earned national recognition with multiple prestigious awards 🏅. Her dedication extends beyond clinical excellence to impactful research, global health, and mentorship 🌍📚. With hands-on experiences at leading institutions like Duke, UNC, and VA Medical Center, her expertise spans brain, breast, liver, and prostate cancer research 🧠💪. Parisa’s unique blend of research, service, and leadership reflects her lifelong commitment to patient care, academic excellence, and transformative cancer therapy 🌟. In addition to her clinical role, she actively contributes as an editorial assistant, social ambassador, and peer-reviewer to renowned medical journals and organizations 📖🤝. She’s a true rising star in oncology 🚀.

Profile

Education 🎓

📍 Chief Resident, Radiation Oncology – Allegheny Health Network, PA (2024–Present) 👩‍⚕️
📍 Residency, Radiation Oncology – Allegheny Health Network, PA (2019–2024) 💉
📍 Internship (PGY-1), Transitional Year – Southern Hills Hospital, Las Vegas, NV (2019–2020) 🏥
📍 M.D. – Kashan University of Medical Sciences, Iran (2007–2014) 🎓🇮🇷
📍 High School – Tehran Farzanegan School, NODET (2000–2007) 🧠🏫
Parisa’s academic journey reflects brilliance from the start, attending Iran’s elite NODET school 🌟. She pursued medicine at KaUMS, consistently ranking top in medical Olympiads 🥇. Her U.S. medical training includes internship and residency in highly reputed institutions, leading to her current leadership as Chief Resident 🧑‍⚕️. Her academic record is peppered with awards, research, and international training, preparing her for a successful future as a physician-scientist and leader in cancer care 🧬🩺.

Experience 👨‍🏫

📍 Chief Resident, Radiation Oncology – AHN (2024–Present)
📍 Research Associate – VA Medical Center, Durham, NC 🧪
📍 Visiting Scholar – Duke, UNC, CCC Las Vegas 🏫
📍 Research Visitor – RAI Lab, Duke University (Glioma Imaging) 🧠
📍 Research Associate – KaUMS, Iran (Probiotics Study) 🧃
📍 Medical Assistant – Advanced Pain Management, NV 💊
📍 Volunteer – Rural Clinics, Pediatrics & Geriatrics Programs 🧒👵
📍 Editorial Assistant – eContour 📘
📍 Communications Intern – RTOG Foundation 💬
Dr. Parisa brings a rich portfolio of clinical and research experience across top U.S. and international institutions 🌍. From clinical research on prostate and brain cancers to hands-on patient care and administrative duties, she is known for her leadership, empathy, and academic dedication 🏥🧠📊.

Awards & Recognitions 🏅

🎖 2024 RTOG Communications Intern
💰 2023 $25K Grant – MRLinac Sarcoma (Benedum Foundation)
🧳 2023 Travel Grants – ARS, ACRO, ACR
🥇 2022 Resident Best Abstract – ABS
🎖 2022 Editorial/Fellow Roles – eContour, The Mednet, NRG
🌟 2022 RePRT Peer Reviewer – Red Journal
🏆 2022 Travel Award – eContour Vulvar Cancer Guidelines
👩‍🎓 Olympiad Champion – 4x Gold in Iran Medical Olympiads
🧠 UNESCO Youth Award – Earthquake Awareness Project
🏅 Sharif University Medal – Math & Graphs Competition
🧪 Ranked 1st in Nationwide Chemistry Lab Exam
📕 Published Short Book – “World of Animals”
📚 Parisa’s excellence is recognized through national and international grants, editorial roles, peer-review selections, and top medical student honors 🏅. From early academic brilliance to clinical and research impact, her accolades reflect a rare blend of intellect, service, and innovation 🌍✨.

Research Interests 🔬

🧠 Radiogenomics – Brain Cancer Imaging (Duke, UNC)
🧬 MR-Linac SBRT – Liver, Pancreatic, Prostate, and Breast Cancers
💪 Strength Training Impact – Radiotherapy in Breast Cancer
🧲 Adaptive Radiation Therapy – CBCT, MRI-based Comparisons
🔍 Treatment Planning – Monte Carlo vs Cone Algorithm
🧫 Biomarker Evaluation – Breast Cancer (KaUMS & Leiden University)
🧃 Probiotics vs Regular Yogurt in Pediatric Diarrhea
🖥 Editorial & Peer Review Roles – Red Journal, The Mednet, eContour
Dr. Shamsesfandabadi’s research bridges advanced imaging, functional planning, and personalized therapy in oncology 🧠. Her projects focus on enhancing precision radiation therapy using radiogenomics, AI-driven adaptive planning, and improving survivorship through integrative approaches 💻💡. She’s driven to optimize outcomes in patients with complex cancers like gliomas, HCC, and pancreatic malignancies, while actively contributing to guidelines and clinical trials 🧪💥. A rising voice in the next-gen of physician-scientists 🌟.

Publications 
  • -Kirichenko, A., Uemura, T., Hasan, S., Lian, Y., Abel, S., Renz, P.,
    Shamsesfandabadi, P., Carpenter, J., Thai, N., “Stereotactic Body Radiotherapy
    (SBRT) for Hepatocellular Carcinoma (HCC) with Single Photon Emission
    Computed Tomography (SPECT) Functional Treatment Planning in Patients with
    Advanced Hepatic Cirrhosis.” Advances in Radiation Oncology (Accepted,
    July 2023).
  • Goss, M., Champ, C., Trombetta, M, Shamsesfandabadi, P., DeMartino, V.,
    Wegner, R., Beriwal, S., Eisen, V. “The Comparison of Collapsed Cone and
    Monte Carlo Algorithms in Tangential Breast Planning.” Journal of Radiotherapy
    in Practice. (April 2023).
  • Mazurowski, M.A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    “Radiogenomics of lower-grade glioma: algorithmically assessed tumor shape
    is associated with tumor genomic subtypes in a multi-institutional study with
    The Cancer Genome Atlas data.” Journal of Neuro-Oncology. 2017, May;
    133(1): 27-35. Cited in PubMed; PMID: 28470431.
  • Mazurowski, M. A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    (2017, March 21). “Radiogenomic analysis of lower grade glioma: a pilot multiinstitutional study shows an association between quantitative image features
    and tumor genomics.” SPIE, The international society for optics and photonics.
  • – Sharif, A., Kheirkhah, D., Shamsesfandabadi, P., et al. “Comparison of Regular
    and Probiotic Yogurts in Treatment of Acute Watery Diarrhea in Children.”
    Journal of Probiotics and Health. 2016, Feb; 5(1): 164.

Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡

Profile

Education 🎓

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖

Experience 👨‍🏫

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬

Research Interests 🔬

Dr. Fadavi’s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. 💻🧬Awards & Recognitions 🏅

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅

Publications 📚